60 DEGREES PHARMACEUTICALS INC. - COMMON STOCK

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

08 May 2024 07:59:00 By Nasdaq GlobeNewswire

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

02 May 2024 07:59:00 By Nasdaq GlobeNewswire

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

03 Apr 2024 07:58:00 By Nasdaq GlobeNewswire

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

14 Mar 2024 07:59:00 By Nasdaq GlobeNewswire

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

20 Feb 2024 07:59:00 By Nasdaq GlobeNewswire

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

08 Feb 2024 07:59:00 By Nasdaq GlobeNewswire

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

31 Jan 2024 11:15:00 By Nasdaq GlobeNewswire

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

30 Jan 2024 09:00:00 By Nasdaq GlobeNewswire

60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting

22 Jan 2024 07:59:00 By Nasdaq GlobeNewswire

60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements

16 Jan 2024 07:59:00 By Nasdaq GlobeNewswire

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

26 Dec 2023 07:59:00 By Nasdaq GlobeNewswire

60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

15 Nov 2023 07:29:00 By Nasdaq GlobeNewswire

60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston

19 Oct 2023 08:31:00 By Nasdaq GlobeNewswire

60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

12 Oct 2023 16:16:00 By Nasdaq GlobeNewswire

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

18 Sep 2023 16:16:00 By Nasdaq GlobeNewswire

60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference

06 Sep 2023 07:31:00 By Nasdaq GlobeNewswire

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

30 Aug 2023 07:32:00 By Nasdaq GlobeNewswire

60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

22 Aug 2023 07:31:00 By Nasdaq GlobeNewswire

60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov

15 Aug 2023 07:31:00 By Nasdaq GlobeNewswire

60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects

31 Jul 2023 07:59:00 By Nasdaq GlobeNewswire